Viyash Scientific Q2 FY27: Revenue up 16.2% to ₹9,879 Million, PAT up 49.4% to ₹1,639 Cr
Viyash Scientific reported Q2 FY27 revenue of ₹9,879 million (up 16.2% YoY) and H1 FY27 revenue of ₹19,343 million (up 17.8% YoY). H1 FY27 PAT increased by 49.4% to ₹1,639 Crore. The company completed the acquisition of BioForLife in Italy and is investing in oncology capabilities and manufacturing capacity.
The substantial increase in revenue and profit, coupled with a strategic acquisition and investments in new capabilities, indicates a significant positive impact on the company's growth trajectory and market position.
The company has reported strong year-on-year growth in revenue and a significant increase in profit after tax, along with strategic acquisitions and investments in future growth areas.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has announced its financial results for the second quarter and first half of fiscal year 2027 (Q2 FY27).
For Q2 FY27, the company reported revenues of ₹9,879 million, marking a 16.2% year-on-year increase. EBITDA stood at ₹2,077 million, up 10.3% YoY. The company's Earnings After Tax (EBT) showed a significant rise of 16.1% to ₹847 million.
In the first half of FY27 (H1 FY27), Viyash Scientific achieved revenues of ₹19,343 million, a 17.8% increase compared to H1 FY26. EBITDA for H1 FY27 grew by 29.9% YoY to ₹4,124 million. Profit After Tax (PAT) for H1 FY27 surged by 49.4% to ₹1,639 million (₹164 Crore). Adjusted PAT, considering normalized ESOP costs, was reported at ₹204 Crore.
The company highlighted strategic developments including the completion of the acquisition of BioForLife in Italy, which strengthens its companion animal platform. Viyash Scientific is also investing in new oncology capabilities, an in-house companion animal manufacturing facility, and expanding its API capacity to meet demand. The management reiterated their focus on disciplined execution, R&D-led growth, and sustainable value creation.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.